Dr. George Tripp Dunham, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1201 Pleasant Valley Rd, Owensboro, KY 42303 Phone: 270-417-4700 |
Dr. John L Hast, M.D. Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 2200 E Parrish Ave, Building A, Owensboro, KY 42303 Phone: 270-926-2273 Fax: 270-926-5200 |
Kishor N Vora, M.D. Internal Medicine - Interventional Cardiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Breckenridge St, Owensboro, KY 42303 Phone: 270-683-8672 Fax: 270-685-8223 |
Dr. Stephen Lee Moore, D.O. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1301 Pleasant Valley Rd, Suite 202, Owensboro, KY 42303 Phone: 270-417-7500 Fax: 270-417-7509 |
Ravi K. Alapati, MD Internal Medicine - Bariatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 2801 New Hartford Rd, Owensboro, KY 42303 Phone: 270-683-3720 Fax: 270-686-7331 |
News Archive
Scientists at Johns Hopkins schools of Public Health and Medicine have, for the first time, identified variants in the gene MYH9 that are associated with increased risk for non-diabetic end stage renal disease (ESRD,) which is the near-loss of kidney function leading to either dialysis of transplant. MYH9, located on the 22 chromosome, is the first gene identified for common forms of kidney disease.
James L. Martin, chairman of the 60 Plus Association, a seniors advocacy group, applauded the Food and Drug Administration's (FDA) decision to remove unapproved colchicine products from the market, and called on drug manufacturers, distributors and pharmacies to help the FDA protect patients from unapproved drugs.
Dallas-based Westmount Realty Capital announced today the sale of approximately 3.9 acres of its landholdings at Westmount Health Campus to Forest Park Realty Partners III for the further expansion of its adjacent Forest Park Medical Center
John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc., announced the submission of an IND application to the Food and Drug Administration to conduct a Phase I trial of its lead, anti-cancer compound, LB-100.
› Verified 3 days ago